A randomized, parallel controlled trial for assessment of the safety, tolerability and efficacy of intravenous or intravesical camrelizumab (SHR-1210) in the treatment of participants with high risk non-muscle invasive bladder cancer
Latest Information Update: 02 Dec 2020
At a glance
- Drugs Camrelizumab (Primary) ; Camrelizumab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Therapeutic Use
- 02 Dec 2020 New trial record